1
|
Williams CR, Jerez C, Klein K, Correa M, Belizán JM, Cormick G. Obstetric violence: a Latin American legal response to mistreatment during childbirth. BJOG 2018; 125:1208-1211. [PMID: 29727059 DOI: 10.1111/1471-0528.15270] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/12/2018] [Indexed: 11/29/2022]
Affiliation(s)
- C R Williams
- Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - C Jerez
- Interdisciplinary Institute of Gender Studies, School of Philosophy and Liberal Arts, University of Buenos Aires (IIEGE, FILO, UBA), Buenos Aires, Argentina
| | - K Klein
- Institute for Clinical Effectiveness and Health Policy (IECS- CONICET), Buenos Aires, Argentina
| | - M Correa
- Institute for Clinical Effectiveness and Health Policy (IECS- CONICET), Buenos Aires, Argentina
| | - J M Belizán
- Institute for Clinical Effectiveness and Health Policy (IECS- CONICET), Buenos Aires, Argentina
| | - G Cormick
- Institute for Clinical Effectiveness and Health Policy (IECS- CONICET), Buenos Aires, Argentina.,Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| |
Collapse
|
2
|
Citadini JM, Brandt R, Williams CR, Gomes FR. Evolution of morphology and locomotor performance in anurans: relationships with microhabitat diversification. J Evol Biol 2018; 31:371-381. [PMID: 29297953 DOI: 10.1111/jeb.13228] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2017] [Revised: 11/18/2017] [Accepted: 12/17/2017] [Indexed: 11/30/2022]
Abstract
The relationships between morphology, performance, behavior and ecology provide evidence for multiple and complex phenotypic adaptations. The anuran body plan, for example, is evolutionarily conserved and shows clear specializations to jumping performance back at least to the early Jurassic. However, there are instances of more recent adaptation to habit diversity in the post-cranial skeleton, including relative limb length. The present study tested adaptive models of morphological evolution in anurans associated with the diversity of microhabitat use (semi-aquatic arboreal, fossorial, torrent, and terrestrial) in species of anuran amphibians from Brazil and Australia. We use phylogenetic comparative methods to determine which evolutionary models, including Brownian motion (BM) and Ornstein-Uhlenbeck (OU) are consistent with morphological variation observed across anuran species. Furthermore, this study investigated the relationship of maximum distance jumped as a function of components of morphological variables and microhabitat use. We found there are multiple optima of limb lengths associated to different microhabitats with a trend of increasing hindlimbs in torrent, arboreal, semi-aquatic whereas fossorial and terrestrial species evolve toward optima with shorter hindlimbs. Moreover, arboreal, semi-aquatic and torrent anurans have higher jumping performance and longer hindlimbs, when compared to terrestrial and fossorial species. We corroborate the hypothesis that evolutionary modifications of overall limb morphology have been important in the diversification of locomotor performance along the anuran phylogeny. Such evolutionary changes converged in different phylogenetic groups adapted to similar microhabitat use in two different zoogeographical regions.
Collapse
Affiliation(s)
- J M Citadini
- Department of Physiology, Bioscience Institute, University of São Paulo, São Paulo, SP, Brazil
| | - R Brandt
- Department of Biology, FFCLRP/USP, Ribeirão Preto, SP, Brazil
| | - C R Williams
- Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia
| | - F R Gomes
- Department of Physiology, Bioscience Institute, University of São Paulo, São Paulo, SP, Brazil
| |
Collapse
|
3
|
Leal AS, Williams CR, Royce DB, Pioli PA, Sporn MB, Liby KT. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Cancer Lett 2017; 394:76-87. [PMID: 28254412 DOI: 10.1016/j.canlet.2017.02.021] [Citation(s) in RCA: 87] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2016] [Revised: 02/07/2017] [Accepted: 02/21/2017] [Indexed: 01/01/2023]
Abstract
Bromodomain inhibitors (JQ1 and I-BET 762) are a new generation of selective, small molecule inhibitors that target BET (bromodomain and extra terminal) proteins. By impairing their ability to bind to acetylated lysines on histones, bromodomain inhibitors interfere with transcriptional initiation and elongation. BET proteins regulate several genes responsible for cell cycle, apoptosis and inflammation. In this study, JQ1 and I-BET 762 decreased c-Myc and p-Erk 1/2 protein levels and inhibited proliferation in pancreatic cancer cells. The tumor microenvironment is known to play an important role in pancreatic cancer, and these drugs suppressed the production of nitric oxide and a variety of inflammatory cytokines, including IL-6, CCL2, and GM-CSF, in both immune and pancreatic cancer cells in vitro. Notably, the bromodomain inhibitors also reduced protein levels of p-Erk 1/2 and p-STAT3 in mouse models of pancreatic cancer. All of these proteins are essential for tumor promotion, progression and metastasis. In conclusion, the bromodomain inhibitors JQ1 and I-BET 762 targeted and suppressed multiple pathways in pancreatic cancer. I-BET 762 and a number of other bromodomain inhibitors are currently being tested in several clinical trials, making them potentially promising drugs for the treatment of pancreatic cancer, an often-fatal disease.
Collapse
Affiliation(s)
- Ana S Leal
- Geisel School of Medicine at Dartmouth, Department of Pharmacology, Hanover, NH, USA; Michigan State University, Department of Pharmacology & Toxicology, East Lansing, MI, USA
| | - Charlotte R Williams
- Geisel School of Medicine at Dartmouth, Department of Pharmacology, Hanover, NH, USA
| | - Darlene B Royce
- Geisel School of Medicine at Dartmouth, Department of Pharmacology, Hanover, NH, USA
| | - Patricia A Pioli
- Geisel School of Medicine at Dartmouth, Department of Microbiology and Immunology, Lebanon, NH, USA
| | - Michael B Sporn
- Geisel School of Medicine at Dartmouth, Department of Pharmacology, Hanover, NH, USA
| | - Karen T Liby
- Geisel School of Medicine at Dartmouth, Department of Pharmacology, Hanover, NH, USA; Michigan State University, Department of Pharmacology & Toxicology, East Lansing, MI, USA.
| |
Collapse
|
4
|
Jensen MP, Petersen WA, Bansemer A, Bharadwaj N, Carey LD, Cecil DJ, Collis SM, Del Genio AD, Dolan B, Gerlach J, Giangrande SE, Heymsfield A, Heymsfield G, Kollias P, Lang TJ, Nesbitt SW, Neumann A, Poellot M, Rutledge SA, Schwaller M, Tokay A, Williams CR, Wolff DB, Xie S, Zipser EJ. THE MIDLATITUDE CONTINENTAL CONVECTIVE CLOUDS EXPERIMENT (MC3E). Bull Am Meteorol Soc 2016; 97:1667-1686. [PMID: 32669729 PMCID: PMC7362300 DOI: 10.1175/bams-d-14-00228.1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
Abstract
The Midlatitude Continental Convective Clouds Experiment (MC3E), a field program jointly led by the U.S. Department of Energy’s Atmospheric Radiation Measurement (ARM) Program and the National Aeronautics and Space Administration’s (NASA) Global Precipitation Measurement (GPM) mission, was conducted in south-central Oklahoma during April–May 2011. MC3E science objectives were motivated by the need to improve our understanding of midlatitude continental convective cloud system life cycles, microphysics, and GPM precipitation retrieval algorithms. To achieve these objectives, a multiscale surface- and aircraft-based in situ and remote sensing observing strategy was employed. A variety of cloud and precipitation events were sampled during MC3E, of which results from three deep convective events are highlighted. Vertical structure, air motions, precipitation drop size distributions, and ice properties were retrieved from multiwavelength radar, profiler, and aircraft observations for a mesoscale convective system (MCS) on 11 May. Aircraft observations for another MCS observed on 20 May were used to test agreement between observed radar reflectivities and those calculated with forward-modeled reflectivity and microwave brightness temperatures using in situ particle size distributions and ice water content. Multiplatform observations of a supercell that occurred on 23 May allowed for an integrated analysis of kinematic and microphysical interactions. A core updraft of 25 m s−1 supported growth of hail and large raindrops. Data collected during the MC3E campaign are being used in a number of current and ongoing research projects and are available through the ARM and NASA data archives.
Collapse
Affiliation(s)
- M P Jensen
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - W A Petersen
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - A Bansemer
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - N Bharadwaj
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - L D Carey
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - D J Cecil
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - S M Collis
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - A D Del Genio
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - B Dolan
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - J Gerlach
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - S E Giangrande
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - A Heymsfield
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - G Heymsfield
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - P Kollias
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - T J Lang
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - S W Nesbitt
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - A Neumann
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - M Poellot
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - S A Rutledge
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - M Schwaller
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - A Tokay
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - C R Williams
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - D B Wolff
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - S Xie
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| | - E J Zipser
- Jensen and Giangrande-Brookhaven National Laboratory, Upton, New York; Petersen, Gerlach, and Wolff-NASA Goddard Space Flight Center, Greenbelt, Maryland, and NASA Wallops Flight Facility, Wallops Island, Virginia; Bansemer and A. Heymsfield-National Center for Atmospheric Research, Boulder, Colorado; Bharadwaj-Pacific Northwest National Laboratory, Richland, Washington; Carey-University of Alabama in Huntsville, Huntsville, Alabama; Cecil and Lang-NASA Marshall Space Flight Center, Huntsville, Alabama; Collis-Argonne National Laboratory, Argonne, Illinois; Del Genio-NASA Goddard Institute for Space Studies, New York, New York; Dolan and Rutledge-Colorado State University, Fort Collins, Colorado; G. Heymsfield and Schwaller-NASA Goddard Space Flight Center, Greenbelt, Maryland; Kollias-McGill University, Montreal, Quebec, Canada; Nesbitt-University of Illinois at Urbana-Champaign, Urbana, Illinois; Neumann and Poellot-University of North Dakota, Grand Forks, North Dakota; Tokay-University of Maryland, Baltimore County, Baltimore, and NASA Goddard Space Flight Center, Greenbelt, Maryland; Williams-University of Colorado, Boulder, Boulder, Colorado; Xie-Lawrence Livermore National Laboratory, Livermore, California; Zipser-University of Utah, Salt Lake City, Utah
| |
Collapse
|
5
|
Faull KJ, Webb C, Williams CR. Desiccation survival time for eggs of a widespread and invasive Australian mosquito species, Aedes (Finlaya) notoscriptus (Skuse). J Vector Ecol 2016; 41:55-62. [PMID: 27232125 DOI: 10.1111/jvec.12194] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Accepted: 11/04/2015] [Indexed: 06/05/2023]
Abstract
The Australian native mosquito Aedes (Finlaya) notoscriptus (Skuse) is closely associated with natural and artificial water holding receptacles. Eggs are laid in habitats where they are exposed to drying conditions as water levels fluctuate. Withstanding desiccation enables survival in challenging environments and increases the potential for establishment in non-native habitats. Until now, the desiccation resistance of Ae. notoscriptus eggs has been unknown despite the historical invasive success of this important dog heartworm and arbovirus vector. Viability and mean survival times of eggs from two Ae. notoscriptus populations (metropolitan areas of Sydney, NSW and Adelaide, SA) were evaluated, with eggs stored under three dryness conditions for up to 367 days. Our results revealed that Ae. notoscriptus eggs can withstand desiccation for extended periods, under a variety of conditions, with approximately 9-13% egg viability recorded after one year. This prolonged egg survival reflects the widespread distribution of this mosquito in Australia and its history of incursions and subsequent establishment in non-native habitats. Differences in mean egg volume were recorded in addition to significantly different egg length to width ratios for the two populations, which may reflect adaptation to biotope of origin and an associated likelihood of drought and drying conditions. The results of this study suggest that the desiccation resistant eggs of Ae. notoscriptus make this species highly adaptable, increasing the risk of movement to non-endemic regions of the world.
Collapse
Affiliation(s)
- K J Faull
- Sansom Institute for Health Research, and School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, 5001.
| | - C Webb
- Department of Medical Entomology, Pathology West - ICPMR Westmead and University of Sydney, Westmead Hospital, Westmead, NSW, Australia, 2145
| | - C R Williams
- Sansom Institute for Health Research, and School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, 5001
| |
Collapse
|
6
|
Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, Hu H, Schiff R, Cook RS, Kurokawa M. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle 2015; 14:648-55. [PMID: 25590338 DOI: 10.4161/15384101.2014.994966] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Approximately 25% of breast cancers overexpress and depend on the receptor tyrosine kinase ERBB2, one of 4 ERBB family members. Targeted therapies directed against ERBB2 have been developed and used clinically, but many patients continue to develop resistance to such therapies. Although much effort has been focused on elucidating the mechanisms of acquired resistance to ERBB2-targeted therapies, the involvement of ERBB4 remains elusive and controversial. We demonstrate that genetic ablation of ERBB4, but not ERBB1-3, led to apoptosis in lapatinib-resistant cells, suggesting that the efficacy of pan-ERBB inhibitors was, at least in part, mediated by the inhibition of ERBB4. Moreover, ERBB4 was upregulated at the protein level in ERBB2+ breast cancer cell lines selected for acquired lapatinib resistance in vitro and in MMTV-Neu mice following prolonged lapatinib treatment. Knockdown of ERBB4 caused a decrease in AKT phosphorylation in resistant cells but not in sensitive cells, suggesting that ERBB4 activated the PI3K/AKT pathway in lapatinib-resistant cells. Importantly, ERBB4 knockdown triggered apoptosis not only in lapatinib-resistant cells but also in trastuzumab-resistant cells. Our results suggest that although ERBB4 is dispensable for naïve ERBB2+ breast cancer cells, it may play a key role in the survival of ERBB2+ cancer cells after they develop resistance to ERBB2 inhibitors, lapatinib and trastuzumab.
Collapse
Key Words
- EGFR
- EGFR, epidermal growth factor receptor
- ERK, extracellular regulated kinase
- FGFR, fibroblast growth factor receptor
- HER, human epidermal growth factor receptor
- HER2
- HER3
- HER4
- Herceptin
- MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
- PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase
- Q-VD-OPh, quinolyl-valyl-O-methylaspartyl-[2,6-difluoro-phenoxy]-methyl ketone
- RTK, receptor tyrosine kinase
Collapse
|
7
|
Leal AS, Williams CR, Sporn MB, Liby KT. Abstract 293: Therapeutic effects of the bromodomain inhibitors JQ1 and I-BET 762 on pancreatic cancer. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Pancreatic cancer is expected to be the second most deadly cancer by 2030 with very few effective therapeutic options to improve patient survival. Bromodomain inhibitors (JQ1 and I-BET 762) are a new generation of chemotherapeutic drugs that target BET proteins, impairing their ability to bind to acetyl modified lysines and therefore interfering with transcriptional initiation and elongation. BET proteins regulate several genes responsible for cell cycle, apoptosis and inflammation. I-BET 762 is currently in clinical trials for cancer and has the advantage of oral administration.
Kras is one of the most common mutated genes in pancreatic cancer (90%); however its protein is a difficult drug target. p-Erk, responsible for several pathways regulating cell survival, is a downstream effector of Kras that has been shown to be essential for the progression and maintenance of pancreatic cancer. LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) and LSL-KrasG12D/+;Pdx-1-Cre (KC) mouse models are commonly used to study pancreatic cancer. KPC mice develop the full spectrum of pancreatic cancer by an average age of 20 weeks. The KC mouse model is commonly used to study pancreatic cancer progression after stimulation with a pancreatic inflammatory agent, such as cerulein.
JQ1 and I-BET 762 reduce the protein levels of p-ERK 1/2 in cells lines derived from a pancreatic tumor or ascites of KPC animals. JQ1 and I-BET 762 are also effective at inhibiting cell growth in human pancreatic cells harboring Kras mutations. When KC mice are injected with LPS to induce inflammation and pancreatitis, p-ERK 1/2 protein levels are significantly increased. This model is being used to test the effects of JQ1 and I-BET 762 after a single LPS injection, in KC mice.
Pancreatic cancer is driven by several cytokines and chemokines, including CCL2 and IL-6, which recruit and regulate the inflammatory cells (macrophages, T cells and MDSC (Myeloid derived suppressor cells) cells) in the tumor. Levels of IL-6 and CCL2 in cell lines developed from KPC mice are reduced when treated with JQ1 and I-BET 762. KC mice stimulated with LPS also have higher levels of CCL2 and IL-6 than mice stimulated with saline.
In conclusion this study showed that the bromodomain inhibitors JQ1 and I-BET 762 had positive effects in suppressing targets of inflammation in pancreatic cancer.
We thank James Bradner for the generous gift of JQ1.
Citation Format: Ana S. Leal, Charlotte R. Williams, Michael B. Sporn, Karen T. Liby. Therapeutic effects of the bromodomain inhibitors JQ1 and I-BET 762 on pancreatic cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 293. doi:10.1158/1538-7445.AM2015-293
Collapse
Affiliation(s)
- Ana S. Leal
- Geisel School of Medicine at Dartmouth, Hanover, NH
| | | | | | | |
Collapse
|
8
|
To C, Royce DB, Williams CR, Risingsong R, Sporn MB, Liby KT. Abstract LB-265: Comparison of oleanane triterpenoids and dimethyl fumarate in lung cancer. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-lb-265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Lung cancer accounts for the highest number of cancer-related deaths in the United States, highlighting the need for better therapies. Nrf2 is an important therapeutic target as activation of this pathway detoxifies harmful insults and reduces oxidative stress. However, the role of Nrf2 in cancer biology is controversial. Protection against oxidative stress and inflammation can confer a survival advantage to tumor cells, leading to a poor prognosis, and constitutive activation of Nrf2 has been detected in numerous tumors. In our study, we examined the role of two clinically relevant classes of Nrf2 activators, the synthetic triterpenoids (CDDO-Im and CDDO-Me) and dimethyl fumarate (DMF) in mouse macrophages (Raw 264.7) and in VC1 lung cancer cells. Although both triterpenoids and DMF activated Nrf2, CDDO-Im and CDDO-Me were more potent than DMF. Specifically, 25-50 nM CDDO-Im or CDDO-Me increased NQO1 and HO-1 expression 100-fold. Conversely, 10 μM of DMF was necessary to elicit the same effect. Additionally, 100 nM of CDDO-Im significantly (p<0.05) reduced ROS production induced by tert-butyl hydroperoxide by 69%, while 10 μM of DMF reduced ROS production by 44%. Moreover, nitric oxide production was significantly decreased by triterpenoids at nanomolar concentrations while DMF had a similar effect at micromolar concentrations (p<0.05). Using microarray analysis, we examined whether these Nrf2 activators target the same genes. Only 52 of 99 Nrf2 genes were targeted by all three compounds, and each drug targeted a unique subset of Nrf2 genes. Notably, CDDO-Im, CDDO-Me and DMF induced HO-1 expression by 9.1, 5.3 and 1.6 fold respectively. We then utilized Nrf2 knockout fibroblasts to confirm that induction of HO-1 expression was regulated via both Nrf2-dependent and Nrf2-independent pathways. To examine the effect of these Nrf2 activators in vivo, A/J mice were injected with vinyl carbamate to induce lung cancer. Beginning one week after initiation, mice were fed drugs in diet for 15 weeks. CDDO-Me was the most effective drug in this model; it reduced the average number and size of tumors by 32% (2.2 ± 0.3) and 76% (0.09 ± 0.01), respectively, compared to controls (3.2 ± 0.2 and 0.4 ± 0.04; p<0.05). Average tumor burden was also reduced by 83% (0.2 ± 0.03), compared to the controls (1.2 ± 0.1; p<0.05). Additionally, the percentage of high-grade tumors significantly decreased from 52% in the controls to 31% in the CDDO-Me group (p<0.05). Though less potent, CDDO-Im had similar effects as CDDO-Me. In contrast, when mice were fed DMF in diet, the average number of tumors increased by 29% (4.1 ± 0.4) compared to controls (3.2± 0.2; p<0.05). The percentage of high-grade tumors in mice fed DMF diet also increased to 63% vs. 52% in the controls (p<0.05). These data indicate that DMF increased the severity of lung carcinogenesis in these mice. Collectively, our study suggests that although CDDO-Im, CDDO-Me and DMF all activate Nrf2, they target distinct genes, resulting in different effects for the prevention of lung cancer.
Citation Format: Ciric To, Darlene B. Royce, Charlotte R. Williams, Renee Risingsong, Michael B. Sporn, Karen T. Liby. Comparison of oleanane triterpenoids and dimethyl fumarate in lung cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-265. doi:10.1158/1538-7445.AM2015-LB-265
Collapse
Affiliation(s)
- Ciric To
- Dartmouth College, Geisel School of Medicine, Hanover, NH
| | | | | | | | | | - Karen T. Liby
- Dartmouth College, Geisel School of Medicine, Hanover, NH
| |
Collapse
|
9
|
Cao M, Onyango EO, Williams CR, Royce DB, Gribble GW, Sporn MB, Liby KT. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol Res 2015; 100:135-47. [PMID: 26238177 DOI: 10.1016/j.phrs.2015.07.024] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Revised: 07/24/2015] [Accepted: 07/26/2015] [Indexed: 01/07/2023]
Abstract
Two new analogues of CDDO-Imidazolide (CDDO-Im), namely 1-[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4(-pyridin-2-yl)-1H-imidazole ("CDDO-2P-Im") and 1-[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4(-pyridin-3-yl)-1H-imidazole ("CDDO-3P-Im") have been synthesized and tested for their potential use as chemopreventive drugs. At nanomolar concentrations, they were equipotent to CDDO-Im for inducing differentiation and apoptosis in U937 leukemia cells. As inflammation and oxidative stress contribute to carcinogenesis, we also assessed their cytoprotective potential. The new compounds suppressed inducible nitric oxide synthase (iNOS) expression in RAW264.7 macrophage-like cells and significantly elevated heme oxygenase-1 (HO-1) and quinone reductase (NQO1) mRNA and protein levels in various mouse tissues in vivo. Most importantly, pharmacokinetic studies performed in vitro in human plasma and in vivo showed that each new analogue was more stable than CDDO-Im. Much higher concentrations of the new derivatives were found in mouse liver, lung, pancreas and kidney after gavage in contrast to CDDO-Im. Because of their better bioavailability and their excellent anti-inflammatory profile in vitro, CDDO-2P-Im and CDDO-3P-Im were tested for prevention in a highly relevant mouse lung cancer model, in which A/J mice develop lung carcinomas after injection of vinyl carbamate, a potent carcinogen. CDDO-2P-Im and CDDO-3P-Im were as effective as CDDO-Im for reducing the size and the severity of the lung tumors.
Collapse
Affiliation(s)
- Martine Cao
- Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH, USA
| | - Evans O Onyango
- Department of Chemistry, Dartmouth College, Hanover, NH, USA
| | - Charlotte R Williams
- Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH, USA
| | - Darlene B Royce
- Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH, USA
| | | | - Michael B Sporn
- Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH, USA
| | - Karen T Liby
- Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH, USA.
| |
Collapse
|
10
|
To C, Ringelberg CS, Royce DB, Williams CR, Risingsong R, Sporn MB, Liby KT. Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. Carcinogenesis 2015; 36:769-81. [PMID: 25939751 DOI: 10.1093/carcin/bgv061] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2015] [Accepted: 04/27/2015] [Indexed: 12/16/2022] Open
Abstract
Lung cancer accounts for the highest number of cancer-related deaths in the USA, highlighting the need for better prevention and therapy. Activation of the Nrf2 pathway detoxifies harmful insults and reduces oxidative stress, thus preventing carcinogenesis in various preclinical models. However, constitutive activation of the Nrf2 pathway has been detected in numerous cancers, which confers a survival advantage to tumor cells and a poor prognosis. In our study, we compared the effects of two clinically relevant classes of Nrf2 activators, dimethyl fumarate (DMF) and the synthetic oleanane triterpenoids, CDDO-imidazolide (CDDO-Im) and CDDO-methyl ester (CDDO-Me) in RAW 264.7 mouse macrophage-like cells, in VC1 lung cancer cells and in the A/J model of lung cancer. Although the triterpenoids and DMF both activated the Nrf2 pathway, CDDO-Im and CDDO-Me were markedly more potent than DMF. All of these drugs reduced the production of reactive oxygen species and inhibited nitric oxide production in RAW264.7 cells, but the triterpenoids were 100 times more potent than DMF in these assays. Microarray analysis revealed that only 52 of 99 Nrf2-target genes were induced by all three compounds, and each drug regulated a unique subset of Nrf2 genes. These drugs also altered the expression of other genes important in lung cancer independent of Nrf2. Although all three compounds enhanced the phosphorylation of CREB, only DMF increased the phosphorylation of Akt. CDDO-Me, at either 12.5 or 50mg/kg of diet, was the most effective drug in our lung cancer mouse model. Specifically, CDDO-Me significantly reduced the average tumor number, size and burden compared with the control group (P < 0.05). Additionally, 52% of the tumors in the control group were high-grade tumors compared with only 14% in the CDDO-Me group. Though less potent, CDDO-Im had similar activity as CDDO-Me. In contrast, 61-63% of the tumors in the DMF groups (400-1200mg/kg diet) were high-grade tumors compared with 52% for the controls (P < 0.05). Additionally, DMF significantly increased the average number of tumors compared with the controls (P < 0.05). Thus, in contrast to the triterpenoids, which effectively reduced pathogenesis in A/J mice, DMF enhanced the severity of lung carcinogenesis in these mice. Collectively, these results suggest that although CDDO-Im, CDDO-Me and DMF all activate the Nrf2 pathway, they target distinct genes and signaling pathways, resulting in opposite effects for the prevention of experimental lung cancer.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Karen T Liby
- Department of Pharmacology, Department of Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA
| |
Collapse
|
11
|
Nicholson J, Ritchie SA, Russell RC, Webb CE, Cook A, Zalucki MP, Williams CR, Ward P, van den Hurk AF. Effects of Cohabitation on the Population Performance and Survivorship of the Invasive Mosquito Aedes albopictus and the Resident Mosquito Aedes notoscriptus (Diptera: Culicidae) in Australia. J Med Entomol 2015; 52:375-385. [PMID: 26334811 DOI: 10.1093/jme/tjv004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Accepted: 12/18/2014] [Indexed: 06/05/2023]
Abstract
The presence of Aedes albopictus (Skuse) in the Torres Strait of northern Australia increases the potential for colonization and establishment on the mainland. However, there is a possibility that native species that occupy the same habitats may influence the population performance of Ae. albopictus, potentially affecting the establishment of this species in Australia. Cohabitation experiments were performed with the endemic Aedes notoscriptus (Skuse), which has been found occupying the same larval habitats as Ae. albopictus in the Torres Strait and is the most widespread container-inhabiting Aedes species in Australia. The influence of environmental factors and cohabitation between the two species was examined using different climates, food resource levels, food resource types, and species densities. Survivorship proportions and a population performance index (λ') were calculated and compared. The consequences of increased Ae. notoscriptus densities were reduced survivorship and λ' for Ae. albopictus. Despite this, the mean λ' of Ae. albopictus and Ae. notoscriptus was consistently ≥ 1.06, indicating both species could increase under all conditions, potentially due to increasing conspecific densities negatively affecting Ae. notoscriptus. The outcomes from this study suggest that the preexisting presence of Ae. notoscriptus may not prevent the establishment of Ae. albopictus in Australia.
Collapse
Affiliation(s)
- J Nicholson
- School of Pathology and Laboratory Medicine, The University of Western Australia, Nedlands, WA 6009, Australia. School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia
| | - S A Ritchie
- School of Public Health, Tropical Medicine and Rehabilitative Sciences, James Cook University, Cairns, QLD 4870, Australia
| | - R C Russell
- Department of Medical Entomology, The University of Sydney, Westmead, NSW 2006, Australia
| | - C E Webb
- Department of Medical Entomology, The University of Sydney, Westmead, NSW 2006, Australia
| | - A Cook
- School of Population Health, The University of Western Australia, Nedlands, WA 6009, Australia
| | - M P Zalucki
- School of Biological Sciences, The University of Queensland, St. Lucia, QLD 4072, Australia
| | - C R Williams
- Sansom Institute for Health Research, The University of South Australia, Adelaide, SA 5000, Australia
| | - P Ward
- School of Biological Sciences, The University of Queensland, St. Lucia, QLD 4072, Australia
| | - A F van den Hurk
- School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia. Public Health Virology, Queensland Health Forensic and Scientific Services, Coopers Plains, QLD 4108, Australia.
| |
Collapse
|
12
|
Liby KT, Williams CR, Risingsong R, Sporn MB, Collins RM, Royce DB. Abstract LB-245: The EGRF receptor inhibitor Erlotinib, alone or in combination with the rexinoid LG100268, is effective for prevention in mouse models of lung and pancreatic cancer with Kras mutations. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-lb-245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Lung cancer and pancreatic cancer are leading causes of cancer deaths, with extremely poor 5 year survival rates for both types of cancer. The epidermal growth factor receptor (EGFR) and its ligands regulate cell growth, and EGFR expression is frequently elevated in lung and pancreatic cancer. Tumors with activating mutations in EGFR are treated clinically with drugs such as erlotinib, a tyrosine kinase EGFR inhibitor. Up to 90% of pancreatic cancers and 35% of lung cancers contain activating mutations in Kras, but tumors with Kras mutations are usually resistant to EGRF inhibitors. Erlotinib is an approved drug for treating pancreatic cancer, but it only extends survival by a few weeks. We have previously shown that the rexinoid LG100268 (268) is effective for prevention of experimental lung and pancreatic cancers with Kras mutations, and a recent clinical trial suggests that the combination of a rexinoid and erlotinib might be useful for treating lung cancer, even in tumors with Kras mutations. In order to test whether this combination of drugs might be useful for prevention of lung cancer, female A/J mice were injected i.p. with vinyl carbamate (16 mg/kg) once a week for two weeks. The carcinogen induces Kras mutations and microscopic adenocarcinomas in the lungs within 4-6 weeks. Starting one week after the last injection of carcinogen, the mice were fed the rexinoid 268 (40 mg/kg diet), erlotinib (150 mg/kg diet) or the combination for 16 weeks. All 3 groups significantly (P < 0.05 for each group vs. control and the combination vs. the individual drugs) reduced the average size of lung tumors by 45-80%, from an average of 3.2 ± 0.6 mm3 in the control group (n = 28) to 1.8 ± 0.4 with erlotinib, 1.1 ± 0.3 with 268 and 0.7 ±0.08 mm3 with the combination (n = 12 per group). The average tumor burden was also significantly reduced 43% by erlotinib, 77% by 268 and 85% by the combination. The total tumor burden per slide was 10.5 ± 1.5 mm3 in the control group but only 2.5 ± 0.5 mm3 in mice fed 268, 6.0 ±1.0 in mice fed erlotinib, and 1.6 ± 0.3 mm3 in mice fed the combination (P < 0.05). The percentage of high grade invasive tumors was also significantly (P < 0.05) reduced from 51% in the control group to 22-34% in mice on a chemopreventive diet. In the LSL-KrasG12D/+;LSL-Trp53R127H/+;Pdx-1-Cre (KPC) mouse model of pancreatic cancer, Kras mutations drive carcinogenesis, and the clinical symptoms and histopathology found in this model replicate the human disease. To test the effectiveness of an EGFR inhibitor in the KPC model, mice were fed erlotinib (150 mg/kg diet), beginning at 4 weeks of age until the mice displayed overt symptoms (cachexia, abdmoninal distension) of pancreatic cancer. Erlotinib significantly (P < 0.05) increased survival compared to the control group (n = 26-27 per group). Average lifespan was extended from an average of 24.7 ± 2.4 weeks in the control group vs. 29.3 ± 2.8 weeks in mice on erlotinib diet, an increase of 4.5 weeks. Ongoing experiments are testing the efficacy of the combination of erlotinib and 268 in the KPC model and studying the mechanism of action of these drugs in Kras-driven models.
Citation Format: Karen T. Liby, Charlotte R. Williams, Renee Risingsong, Michael B. Sporn, Ryan M. Collins, Darlene B. Royce. The EGRF receptor inhibitor Erlotinib, alone or in combination with the rexinoid LG100268, is effective for prevention in mouse models of lung and pancreatic cancer with Kras mutations. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-245. doi:10.1158/1538-7445.AM2014-LB-245
Collapse
|
13
|
To C, Kim EH, Royce DB, Williams CR, Collins RM, Risingsong R, Sporn MB, Liby KT. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res (Phila) 2014; 7:698-707. [PMID: 24817481 DOI: 10.1158/1940-6207.capr-14-0047] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Poly-ADP ribose polymerase (PARP) inhibitors are effective for the treatment of BRCA-deficient tumors. Women with these mutations have an increased risk of developing breast cancer and would benefit from effective chemoprevention. This study examines whether the PARP inhibitors, veliparib and olaparib, delay mammary gland tumor development in a BRCA1-deficient (BRCA1(Co/Co);MMTV-Cre;p53(+/-)) mouse model. In dose de-escalation studies, mice were fed with control, veliparib (100 mg/kg diet), or olaparib (200, 100, 50, or 25 mg/kg diet) continuously for up to 43 weeks. For intermittent dosing studies, mice cycled through olaparib (200 mg/kg diet) for 2 weeks followed by a 4-week rest period on control diet. To examine biomarkers, mice were fed with olaparib using the intermittent dosing regimen and mammary glands were evaluated by immunohistochemistry. In mice treated with veliparib or olaparib (200 mg/kg diet), the average age of the first detectable tumor was delayed by 2.4 and 6.5 weeks, respectively, compared with controls. Olaparib also increased the average lifespan of mice by 7 weeks. In dose de-escalation studies, lower concentrations of olaparib delayed tumor development but were less effective than the highest dose. When fed intermittently, olaparib delayed the onset of the first palpable tumor by 5.7 weeks and significantly reduced proliferation and induced apoptosis in hyperplastic mammary glands. In summary, veliparib and olaparib are effective for delaying tumor development and extending the lifespan of BRCA1-deficient mice, and intermittent dosing with olaparib was as effective as continuous dosing. These results suggest that the use of PARP inhibitors is a promising chemopreventive option.
Collapse
Affiliation(s)
- Ciric To
- Authors' Affiliations: Departments of Pharmacology, and
| | - Eun-Hee Kim
- Authors' Affiliations: Departments of Pharmacology, and
| | | | | | | | | | | | - Karen T Liby
- Authors' Affiliations: Departments of Pharmacology, and Medicine, Dartmouth Medical School, Hanover, New Hampshire
| |
Collapse
|
14
|
Williams CR, Bees MA. Mechanistic modeling of sulfur-deprived photosynthesis and hydrogen production in suspensions of Chlamydomonas reinhardtii. Biotechnol Bioeng 2013; 111:320-35. [PMID: 24026984 PMCID: PMC3920635 DOI: 10.1002/bit.25023] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2013] [Revised: 07/26/2013] [Accepted: 08/09/2013] [Indexed: 11/28/2022]
Abstract
The ability of unicellular green algal species such as Chlamydomonas reinhardtii to produce hydrogen gas via iron-hydrogenase is well known. However, the oxygen-sensitive hydrogenase is closely linked to the photosynthetic chain in such a way that hydrogen and oxygen production need to be separated temporally for sustained photo-production. Under illumination, sulfur-deprivation has been shown to accommodate the production of hydrogen gas by partially-deactivating O2 evolution activity, leading to anaerobiosis in a sealed culture. As these facets are coupled, and the system complex, mathematical approaches potentially are of significant value since they may reveal improved or even optimal schemes for maximizing hydrogen production. Here, a mechanistic model of the system is constructed from consideration of the essential pathways and processes. The role of sulfur in photosynthesis (via PSII) and the storage and catabolism of endogenous substrate, and thus growth and decay of culture density, are explicitly modeled in order to describe and explore the complex interactions that lead to H2 production during sulfur-deprivation. As far as possible, functional forms and parameter values are determined or estimated from experimental data. The model is compared with published experimental studies and, encouragingly, qualitative agreement for trends in hydrogen yield and initiation time are found. It is then employed to probe optimal external sulfur and illumination conditions for hydrogen production, which are found to differ depending on whether a maximum yield of gas or initial production rate is required. The model constitutes a powerful theoretical tool for investigating novel sulfur cycling regimes that may ultimately be used to improve the commercial viability of hydrogen gas production from microorganisms. Biotechnol. Bioeng. 2014;111: 320–335. © 2013 The Authors. Biotechnology and Bioengineering Published by Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- C R Williams
- British Antarctic Survey, Natural Environment Research Council, High Cross, Madingley Road, Cambridge, CB3 0ET, UK.
| | | |
Collapse
|
15
|
Kaidery NA, Banerjee R, Yang L, Smirnova NA, Hushpulian DM, Liby KT, Williams CR, Yamamoto M, Kensler TW, Ratan RR, Sporn MB, Beal MF, Gazaryan IG, Thomas B. Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxid Redox Signal 2013; 18:139-57. [PMID: 22746536 PMCID: PMC3514006 DOI: 10.1089/ars.2011.4491] [Citation(s) in RCA: 130] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
UNLABELLED Although the etiology of Parkinson's disease (PD) remains unclear, ample empirical evidence suggests that oxidative stress is a major player in the development of PD and in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity. Nuclear factor E2-related factor 2 (Nrf2) is a redox-sensitive transcription factor that upregulates a battery of antioxidant response element (ARE)-driven antioxidative and cytoprotective genes that defend against oxidative stress. AIMS We evaluated whether the strategy of activation of Nrf2 and its downstream network of cytoprotective genes with small molecule synthetic triterpenoids (TP) attenuate MPTP-induced PD in mice. RESULTS We show that synthetic TP are thus far the most potent and direct activators of the Nrf2 pathway using a novel Neh2-luciferase reporter. They upregulate several cytoprotective genes, including those involved in glutathione biosynthesis in vitro. Oral administration of TP that were structurally modified to penetrate the brain-induced messenger RNA and protein levels for a battery of Nrf2-dependent cytoprotective genes reduced MPTP-induced oxidative stress and inflammation, and ameliorated dopaminergic neurotoxicity in mice. The neuroprotective effect of these TP against MPTP neurotoxicity was dependent on Nrf2, since treatment with TP in Nrf2 knockout mice failed to block against MPTP neurotoxicity and induce Nrf2-dependent cytoprotective genes. INNOVATION Extremely potent synthetic TP that are direct activators of the Nrf2 pathway block dopaminergic neurodegeneration in the MPTP mouse model of PD. CONCLUSION Our results indicate that activation of Nrf2/antioxidant response element (ARE) signaling by synthetic TP is directly associated with their neuroprotective effects against MPTP neurotoxicity and suggest that targeting the Nrf2/ARE pathway is a promising approach for therapeutic intervention in PD.
Collapse
Affiliation(s)
- Navneet Ammal Kaidery
- Department of Pharmacology & Toxicology, Georgia Health Sciences University, Augusta, GA 30912, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Tran K, Risingsong R, Royce DB, Williams CR, Sporn MB, Pioli PA, Gediya LK, Njar VC, Liby KT. The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. Carcinogenesis 2012; 34:199-210. [PMID: 23042302 DOI: 10.1093/carcin/bgs319] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Novel drugs and drug combinations are needed for the chemoprevention and treatment of cancer. We show that the histone deacetylase inhibitor vorinostat [suberoylanilide hydroxamic acid (SAHA)] and the methyl ester or ethyl amide derivatives of the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO-Me and CDDO-Ea, respectively) cooperated to inhibit the de novo synthesis of nitric oxide in RAW 264.7 macrophage-like cells and in primary mouse peritoneal macrophages. Additionally, SAHA enhanced the ability of synthetic triterpenoids to delay formation of estrogen receptor-negative mammary tumors in MMTV-polyoma middle T (PyMT) mice. CDDO-Me (50 mg/kg diet) and SAHA (250 mg/kg diet) each significantly delayed the initial development of tumors by 4 (P < 0.001) and 2 (P < 0.05) weeks, respectively, compared with the control group in the time required to reach 50% tumor incidence. CDDO-Ea (400 mg/kg diet), as a single agent, did not delay tumor development. The combination of either triterpenoid with SAHA was significantly more potent than the individual drugs for delaying tumor development, with a 7 week (P < 0.001) delay before 50% tumor incidence was reached. SAHA, alone and in combination with CDDO-Me, also significantly (P < 0.05) inhibited the infiltration of tumor-associated macrophages into the mammary glands of PyMT mice and levels of the chemokine macrophage colony-stimulating factor in primary PyMT tumor cells. In addition, SAHA and the synthetic triterpenoids cooperated to suppress secreted levels of the pro-angiogenic factor matrix metalloproteinase-9. Similar results were observed in mouse models of pancreatic and lung cancer. At concentrations that were anti-inflammatory, SAHA had no effect on histone acetylation. These studies suggest that both SAHA and triterpenoids effectively delay tumorigenesis, thereby demonstrating a promising, novel drug combination for chemoprevention.
Collapse
Affiliation(s)
- Kim Tran
- Department of Pharmacology or Medicine, Dartmouth Medical School, Hanover, NH 03755, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Tran K, Risingsong R, Royce D, Williams CR, Sporn MB, Liby K. The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. Cancer Prev Res (Phila) 2012; 5:726-34. [PMID: 22401982 DOI: 10.1158/1940-6207.capr-11-0404] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Novel drugs are needed for the prevention and treatment of breast cancer. Synthetic triterpenoids are a promising new class of compounds with activity in a variety of preclinical cancer models. We tested activity of the methyl ester derivative of the synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO-Me), in a relevant model of estrogen receptor-negative breast cancer, the polyoma-middle T (PyMT), in which the oncoprotein drives carcinogenesis. The developing tumors recapitulate key features of the human disease. Mice were fed CDDO-Me (50 mg/kg diet), starting at 4 weeks of age. CDDO-Me significantly increased the age of mice at onset of first tumor (P < 0.001) by an average of 4.3 weeks and overall survival (P < 0.001) by 5.2 weeks. The drug also inhibited the infiltration of tumor-associated macrophages into mammary glands of PyMT mice at 12 weeks of age and reduced levels of the chemokines CXCL12 and CCL2 in primary PyMT mammary tumor cells. Treatment with this multifunctional drug also inhibited secretion of matrix metalloproteinase-9 in primary tumor cells from PyMT mice and decreased proliferation of these cells by inhibiting cyclin D1 and decreasing phosphorylation of epidermal growth factor receptor and STAT3.
Collapse
Affiliation(s)
- Kim Tran
- Department of Medicine, Dartmouth Medical School, Hanover, NH 03755, USA
| | | | | | | | | | | |
Collapse
|
18
|
Tran KM, Risingsong R, Royce D, Williams CR, Sporn MB, Liby K. Abstract A103: The synthetic triterpenoid CDDO-methyl ester targets tumor-associated macrophages to delay carcinogenesis in the PyMT model of estrogen receptor negative breast cancer. Cancer Prev Res (Phila) 2011. [DOI: 10.1158/1940-6207.prev-11-a103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Breast cancer is the most common cancer among women in the United States. The incidence rates of breast cancer are no longer significantly declining, and approximately 40,000 women die from the disease each year. Hence, novel drugs are needed for the prevention and treatment of the disease. Synthetic triterpenoids are a promising new class of compounds with chemopreventive activity in a variety of preclinical cancer models. We tested the methyl ester derivative of the synthetic triterpenoid, 2-cyano-3, 12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO-Me), in a relevant model of ER-negative breast cancer. In this mouse model, the polyoma-middle T (PyMT) oncoprotein drives carcinogenesis in the mammary gland. The developing tumors recapitulate key features of the human disease including significant infiltration of tumor-associated macrophages (TAM). Depletion of TAMs has been previously shown to delay tumor progression. PyMT mice were fed CDDO-Me (50 mg/kg diet), starting at 4 weeks of age. CDDO-Me significantly increased the age of mice at onset of first tumor by an average of 4.3 weeks (P < 0.001) and overall survival by 5.2 weeks (P < 0.001). CDDO-Me significantly (P < 0.05) inhibited the infiltration of TAMs into mammary glands of PyMT mice along with levels of the chemokines CXCL12 and CCL2 in primary PyMT mammary tumor cells. Treatment with CDDO-Me also inhibited secretion of MMP-9 in primary tumor cells from PyMT mice and decreased proliferation of these cells by inhibiting cyclin D1 and decreasing phosphorylation of EGFR and STAT3, key breast cancer biomarkers. Thus, CDDO-Me delayed breast carcinogenesis via inhibition of TAM infiltration and by inhibition of key pathways in breast carcinogenesis. Taken together, these findings implicate CDDO-Me as a promising chemopreventive agent for ER-negative breast cancer via inhibition of TAM infiltration and diverse oncogenic pathways.
Citation Information: Cancer Prev Res 2011;4(10 Suppl):A103.
Collapse
|
19
|
Kim EH, Deng C, Sporn MB, Royce DB, Risingsong R, Williams CR, Liby KT. CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice. Cancer Prev Res (Phila) 2011; 5:89-97. [PMID: 21933912 DOI: 10.1158/1940-6207.capr-11-0359] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
The breast cancer-associated gene 1 (BRCA1) is the most frequently mutated tumor suppressor gene in familial breast cancers. Mutations in BRCA1 also predispose to other types of cancers, pointing to a fundamental role of this pathway in tumor suppression and emphasizing the need for effective chemoprevention in these high-risk patients. Because the methyl ester of the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO-Me) is a potent chemopreventive agent, we tested its efficacy in a highly relevant mouse model of BRCA1-mutated breast cancer. Beginning at 12 weeks of age, Brca1(Co/Co); MMTV-Cre;p53(+/-) mice were fed powdered control diet or diet containing CDDO-Me (50 mg/kg diet). CDDO-Me significantly (P < 0.05) delayed tumor development in the Brca1-mutated mice by an average of 5.2 weeks. We also observed that levels of ErbB2, p-ErbB2, and cyclin D1 increased in a time-dependent manner in the mammary glands in Brca1-deficient mice, and CDDO-Me inhibited the constitutive phosphorylation of ErbB2 in tumor tissues from these mice. In BRCA1-deficient cell lines, the triterpenoids directly interacted with ErbB2, decreased constitutive phosphorylation of ErbB2, inhibited proliferation, and induced G(0)-G(1) arrest. These results suggest that CDDO-Me has the potential to prevent BRCA1-mutated breast cancer.
Collapse
Affiliation(s)
- Eun-Hee Kim
- Department of Medicine, Dartmouth Medical School, Hanover, NH 03755, USA
| | | | | | | | | | | | | |
Collapse
|
20
|
Liby KT, Royce DB, Risingsong R, Williams CR, Sporn MB. Abstract 2523: Synthetic triterpenoids protect against toxicity and enhance the efficacy of treatment with carboplatin/paclitaxel in experimental lung cancer. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-2523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Lung cancer remains the leading cause of cancer deaths worldwide, with no real improvement in 5 yr survival rates in over 30 yrs. While prevention offers the most promising approach for reducing mortality, new drugs are clearly needed. We have previously shown that synthetic triterpenoids, including the methyl ester (Me) and ethyl amide (EA) of CDDO (2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid), are effective for prevention and treatment of experimental lung cancer; CDDO-Me is currently in early clinical trials. When used for treatment of lung cancer in A/J mice, the triterpenoids caused growth-arrest rather than tumor regression, so we tested the triterpenoids in combination with carboplatin and paclitaxel, standard chemotherapeutic agents used to treat human lung cancer. Female A/J mice were injected i.p. with vinyl carbamate to induce lung cancer; adenocarcinomas are visible on lung sections as early as 4 wks after initiation. In a pilot study, mice were fed triterpenoids and received 5 injections of carboplatin (50 mg/kg) and paclitaxel (15 mg/kg), one wk apart, beginning eight wks after initiation. This protocol was toxic in the mice treated with carboplatin/paclitaxel alone, as only 38% (3 of 8) mice survived. In contrast, 88% (14 of 16) of the mice survived when treated with triterpenoids in combination with carboplatin/ paclitaxel. In a second study, lung cancer was induced by vinyl carbamate, but treatment was delayed until 12 wks after initiation, and the 5 carboplatin/ paclitaxel injections were given every other wk instead of every wk. Survival improved to 91% in the carboplatin/paclitaxel group (21 of 23 mice) and was 97% (31 of 32 mice) in the groups given triterpenoid in combination with carboplatin/paclitaxel. Although treatment with carboplatin/paclitaxel alone significantly (P < 0.05) reduced total tumor volume by 81% compared to the control group (16.1 mm3 for the controls vs. 3.1 mm3 for the group treated with carboplatin/paclitaxel), treatment with the combination of CDDO-EA (800 mg/kg diet) and carboplatin/paclitaxel reduced tumor volume to 1.1 mm3, a 93% reduction compared to the controls (P < 0.05 vs. control and carboplatin/paclitaxel alone). In VC1 lung cancer cells derived from a tumor from an A/J mouse, CDDO-EA directly interacted with IKK and cyclin D1, blocked the degradation of IKBα in cells treated with TNFα, decreased inhibited proliferation by decreasing cyclin D1 levels and increasing p21, and induced apoptosis. Ongoing studies will determine whether the combination of CDDO-EA and carboplatin/paclitaxel induces apoptosis in these tumors in vivo and will explore the mechanisms of action for the protection of the triterpenoids against carboplatin/paclitaxel toxicity in normal tissues while simultaneously enhancing the therapeutic effect in lung cancer. Supported by NIH grant R01 CA78814 and Reata Pharmaceuticals, Inc.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2523. doi:10.1158/1538-7445.AM2011-2523
Collapse
|
21
|
Bader CA, Williams CR. Eggs of the Australian saltmarsh mosquito, Aedes camptorhynchus, survive for long periods and hatch in instalments: implications for biosecurity in New Zealand. Med Vet Entomol 2011; 25:70-76. [PMID: 20840222 DOI: 10.1111/j.1365-2915.2010.00908.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The Australian saltmarsh mosquito, Aedes camptorhynchus (Diptera: Culicidae), is a significant biting pest and disease vector and is the subject of an eradication programme in New Zealand (NZ), where it has been resident for more than 10 years. To better understand the ecology of this common and widespread pest, we studied egg longevity and hatching patterns in the laboratory. By regularly testing for the presence of viable embryos, we found that eggs may last more than 15 months when stored dry (13% viable at this time). Eggs display instalment hatching, with no more than 56% of a batch hatching upon first inundation. Further hatching may occur for at least six inundations and some unhatched eggs may remain viable even after this. Variation in hatching rates can be observed using different water types, with weaker hatching media stimulating lower hatching rates spread over more inundations. By applying average hatching rates to a non-linear model of natural egg attrition, we showed that egg batches exposed to three inundations should be exhausted (zero live eggs present) in approximately 11 months at the conditions tested here. These findings have implications for the current eradication programme for Ae. camptorhynchus in NZ and for our understanding of the ecology of a widespread and common disease vector in Australia.
Collapse
Affiliation(s)
- C A Bader
- Mosquitoes and Public Health Research Group, Sansom Institute for Health Research, University of South Australia, Adelaide, SA, Australia
| | | |
Collapse
|
22
|
Liby KT, Royce DB, Risingsong R, Williams CR, Maitra A, Hruban RH, Sporn MB. Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev Res (Phila) 2010; 3:1427-34. [PMID: 20959520 DOI: 10.1158/1940-6207.capr-10-0197] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and is nearly always fatal. Whereas early detection offers the most promising approach for reducing the mortality of this disease, there is still a need to develop effective drugs for the prevention and treatment of pancreatic cancer. We tested two promising classes of noncytotoxic drugs, synthetic oleanane triterpenoids and rexinoids, for the prevention of carcinogenesis in the highly relevant LSL-Kras(G12D/+);LSL-Trp53(R127H/+);Pdx-1-Cre (KPC) mouse model of pancreatic cancer. KPC transgenic mice closely recapitulate the genetic mutations, clinical symptoms, and histopathology found in human pancreatic cancer. Beginning at 4 weeks of age, mice were fed powdered control diet or a diet containing the triterpenoids CDDO-methyl ester (CDDO-Me) or CDDO-ethyl amide, the rexinoid LG100268 (LG268), or the combination, until the mice displayed overt symptoms of pancreatic cancer. CDDO-Me, LG268, the combination of CDDO-Me and LG268, and the combination of CDDO-ethyl amide and LG268, all significantly (P < 0.05) increased survival in the KPC mice by 3 to 4 weeks. Recent studies have shown that gemcitabine, the current standard of care for human pancreatic cancer, does not extend survival in KPC mice. In cell lines developed from the KPC mice, the triterpenoids directly interact with both signal transducer and activator of transcription 3 and IκB kinase (IKK) to decrease constitutive interleukin-6 secretion, inhibit constitutive signal transducer and activator of transcription 3 phosphorylation, and block the degradation of IκBα when challenged with tumor necrosis factor α. These results suggest that oleanane triterpenoids and rexinoids have the potential to prevent pancreatic cancer.
Collapse
Affiliation(s)
- Karen T Liby
- Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire 03755, USA.
| | | | | | | | | | | | | |
Collapse
|
23
|
Christie AE, Stevens JS, Bowers MR, Chapline MC, Jensen DA, Schegg KM, Goldwaser J, Kwiatkowski MA, Pleasant TK, Shoenfeld L, Tempest LK, Williams CR, Wiwatpanit T, Smith CM, Beale KM, Towle DW, Schooley DA, Dickinson PS. Identification of a calcitonin-like diuretic hormone that functions as an intrinsic modulator of the American lobster, Homarus americanus, cardiac neuromuscular system. ACTA ACUST UNITED AC 2010; 213:118-27. [PMID: 20008368 DOI: 10.1242/jeb.037077] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
In insects, a family of peptides with sequence homology to the vertebrate calcitonins has been implicated in the control of diuresis, a process that includes mixing of the hemolymph. Here, we show that a member of the insect calcitonin-like diuretic hormone (CLDH) family is present in the American lobster, Homarus americanus, serving, at least in part, as a powerful modulator of cardiac output. Specifically, during an ongoing EST project, a transcript encoding a putative H. americanus CLDH precursor was identified; a full-length cDNA was subsequently cloned. In silico analyses of the deduced prepro-hormone predicted the mature structure of the encoded CLDH to be GLDLGLGRGFSGSQAAKHLMGLAAANFAGGPamide (Homam-CLDH), which is identical to a known Tribolium castaneum peptide. RT-PCR tissue profiling suggests that Homam-CLDH is broadly distributed within the lobster nervous system, including the cardiac ganglion (CG), which controls the movement of the neurogenic heart. RT-PCR analysis conducted on pacemaker neuron- and motor neuron-specific cDNAs suggests that the motor neurons are the source of the CLDH message in the CG. Perfusion of Homam-CLDH through the isolated lobster heart produced dose-dependent increases in both contraction frequency and amplitude and a dose-dependent decrease in contraction duration, with threshold concentrations for all parameters in the range 10(-11) to 10(-10) mol l(-1) or less, among the lowest for any peptide on this system. This report is the first documentation of a decapod CLDH, the first demonstration of CLDH bioactivity outside the Insecta, and the first detection of an intrinsic neuropeptide transcript in the crustacean CG.
Collapse
Affiliation(s)
- A E Christie
- Center for Marine Functional Genomics, Mount Desert Island Biological Laboratory, PO Box 35, Old Bar Harbor Road, Salisbury Cove, ME 04672, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
We recorded the activity of pontine omnipause neurons (OPNs) in two macaques during saccadic eye movements and blinks. As previously reported, we found that OPNs fire tonically during fixation and pause about 15 ms before a saccadic eye movement. In contrast, for blinks elicited by air puffs, the OPNs paused <2 ms before the onset of the blink. Thus the burst in the agonist orbicularis oculi motoneurons (OOMNs) and the pause in the antagonist levator palpabrae superioris motoneurons (LPSMNs) necessarily precede the OPN pause. For spontaneous blinks there was no correlation between blink and pause onsets. In addition, the OPN pause continued for 40-60 ms after the time of the maximum downward closing of the eyelids, which occurs around the end of the OOMN burst of firing. LPSMN activity is not responsible for terminating the OPN pause because OPN resumption was very rapid, whereas the resumption of LPSMN firing during the reopening phase is gradual. OPN pause onset does not directly control blink onset, nor does pause offset control or encode the transition between the end of the OOMN firing and the resumption of the LPSMNs. The onset of the blink-related eye transients preceded both blink and OPN pause onsets. Therefore they initiated while the saccadic short-lead burst neurons were still fully inhibited by the OPNs and cannot be saccadic in origin. The abrupt dynamic change of the vertical eye transients from an oscillatory behavior to a single time constant exponential drift predicted the resumption of the OPNs.
Collapse
Affiliation(s)
- K P Schultz
- Department of Vision Sciences and Vision Science Research Center, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | | | | |
Collapse
|
25
|
Liby K, Risingsong R, Royce DB, Williams CR, Ma T, Yore MM, Sporn MB. Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. Cancer Prev Res (Phila) 2009; 2:1050-8. [PMID: 19952361 DOI: 10.1158/1940-6207.capr-09-0085] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
We tested members of two noncytotoxic classes of drugs, synthetic oleanane triterpenoids and rexinoids, both as individual agents and in combination, for the prevention and treatment of carcinogenesis in a highly relevant animal model of lung cancer. Lung adenocarcinomas were induced in A/J mice by injection of the carcinogen vinyl carbamate. Mice were fed drugs in diet, beginning 1 week after the carcinogen challenge for prevention or 8 weeks later for treatment. The number, size, and severity of tumors in the lungs were then evaluated. In the prevention studies, the triterpenoids CDDO-ethyl amide and CDDO-methyl ester reduced the average tumor burden (ATB) in the lungs 86% to 92%, respectively, compared with the controls, and the rexinoid LG100268 (268) reduced ATB by 50%. The combination of CDDO-ethyl amide and 268 reduced ATB by 93%. We show for the first time that these drugs also were highly effective for treatment of experimental lung cancer, and all triterpenoid and rexinoid combinations reduced ATB 85% to 87% compared with the control group. The triterpenoids also potently inhibited proliferation of VC1 mouse lung carcinoma cells and directly interacted with key regulatory proteins in these cells. In contrast, the rexinoids had little antiproliferative activity in VC1 cells but were potent inhibitors of the toll-like receptor pathway in macrophage-like cells. Triterpenoids and rexinoids are multifunctional, well-tolerated drugs that target different signaling pathways and are thus highly effective for prevention and treatment of experimental lung cancer.
Collapse
Affiliation(s)
- Karen Liby
- Department of Pharmacology, Dartmouth Medical School, Hanover, NH 03755, USA.
| | | | | | | | | | | | | |
Collapse
|
26
|
Rapley LP, Johnson PH, Williams CR, Silcock RM, Larkman M, Long SA, Russell RC, Ritchie SA. A lethal ovitrap-based mass trapping scheme for dengue control in Australia: II. Impact on populations of the mosquito Aedes aegypti. Med Vet Entomol 2009; 23:303-316. [PMID: 19941596 DOI: 10.1111/j.1365-2915.2009.00834.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
In Cairns, Australia, the impacts on Aedes aegypti L. (Diptera: Culicidae) populations of two types of 'lure & kill' (L&K) lethal ovitraps (LOs), the standard lethal ovitrap (SLO) and the biodegradable lethal ovitrap (BLO) were measured during three mass-trapping interventions. To assess the efficacy of the SLO, two interventions (one dry season and one wet season) were conducted in three discrete areas, each lasting 4 weeks, with the following treatments: (i) SLOs (>200 traps, approximately 4/premise), BG-sentinel traps (BGSs; approximately 15, 1/premise) and larval control (container reduction and methoprene treatment) and (ii) larval control alone, and (iii) untreated control. Female Ae. aegypti populations were monitored for 4 weeks pre- and post-treatment in all three areas using BGSs and sticky ovitraps (SOs) or non-lethal regular ovitraps (ROs). In the dry season, 206 SLOs and 15 BGSs set at 54 and 15 houses, respectively, caught and killed an estimated 419 and 73 female Ae. aegypti, respectively. No significant decrease in collection size of female Ae. aegypti could be attributed to the treatments. In the wet season, 243 SLOs and 15 BGSs killed approximately 993 and 119 female Ae. aegypti, respectively. The mean number of female Ae. aegypti collected after 4 weeks with SOs and BGSs was significantly less than the control (LSD post-hoc test). The third mass-trapping intervention was conducted using the BLO during the wet season in Cairns. For this trial, three treatment areas were each provided with BLOs (>500, approximately 4/premise) plus larval control, and an untreated control area was designated. Adult female Ae. aegypti were collected for 4 weeks pre- and post-treatment using 15 BGSs and 20 SOs. During this period, 53.2% of BLOs contained a total of 6654 Ae. aegypti eggs. Over the intervention period, collections of Ae. aegypti in the treatment areas were significantly less than in the control area for BGSs but not SOs. An influx of relatively large numbers of young females may have confounded the measurement of changes in populations of older females in these studies. This is an important issue, with implications for assessing delayed action control measures, such as LOs and parasites/pathogens that aim to change mosquito age structure. Finally, the high public acceptability of SLOs and BLOs, coupled with significant impacts on female Ae. aegypti populations in two of the three interventions reported here, suggest that mass trapping with SLOs and BLOs can be an effective component of a dengue control strategy.
Collapse
Affiliation(s)
- L P Rapley
- School of Public Health, Tropical Medicine and Rehabilitation Sciences, James Cook University, Cairns, QLD 4870, Australia
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, McCulloch CC, Silkworth JB, Taguchi K, Yamamoto M, Williams CR, Liby KT, Sporn MB, Sutter TR, Kensler TW. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis 2009; 30:1024-31. [PMID: 19386581 DOI: 10.1093/carcin/bgp100] [Citation(s) in RCA: 212] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Loss of NF-E2-related factor 2 (Nrf2) signaling increases susceptibility to acute toxicity, inflammation and carcinogenesis in mice due to the inability to mount adaptive responses. In contrast, disruption of Keap1 (a cytoplasmic modifier of Nrf2 turnover) protects against these stresses in mice, although inactivating mutations in Keap1 have been identified recently in some human cancers. Global characterization of Nrf2 activation is important to exploit this pathway for chemoprevention in healthy, yet at-risk individuals and also to elucidate the consequences of hijacking the pathway in Keap1-mutant human cancers. Liver-targeted conditional Keap1-null, Albumin-Cre:Keap1((flox/-)) (CKO) mice provide a model of genetic activation of Nrf2 signaling. By coupling global gene expression analysis of CKO mice with analysis of pharmacologic activation using the synthetic oleanane triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im), we are able to gain insight into pathways affected by Nrf2 activation. CDDO-Im is an extremely potent activator of Nrf2 signaling. CKO mice were used to identify genes modulated by genetic activation of Nrf2 signaling. The CKO response was compared with hepatic global gene expression changes in wild-type mice treated with CDDO-Im at a maximal Nrf2 activating dose. The results show that genetic and pharmacologic activation of Nrf2 signaling modulates pathways beyond detoxication and cytoprotection, with the largest cluster of genes associated with lipid metabolism. Genetic activation of Nrf2 results in much larger numbers of detoxication and lipid metabolism gene changes. Additionally, analysis of pharmacologic activation suggests that Nrf2 is the primary mediator of CDDO-Im activity, though other cell-signaling targets are also modulated following an oral dose of 30 micromol/kg.
Collapse
Affiliation(s)
- Melinda S Yates
- Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Kokkinn MJ, Duval DJ, Williams CR. Modelling the ecology of the coastal mosquitoes Aedes vigilax and Aedes camptorhynchus at Port Pirie, South Australia. Med Vet Entomol 2009; 23:85-91. [PMID: 19239618 DOI: 10.1111/j.1365-2915.2008.00787.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Two mosquito species, Aedes camptorhynchus (Thomson) and Aedes vigilax (Skuse) (Diptera: Culicidae) are responsible for significant nuisance biting and disease transmission in southern coastal Australia. Mosquito abundance, tide height, temperature and rainfall data were collected over three summer seasons (2002, 2003, 2004) at Port Pirie, South Australia and subjected to statistical analysis to develop ecological models for predicting problem mosquito outbreaks. A logistic regression model for Ae. camptorhynchus gave a predictive R(2) of 0.30 using mean air temperature, whereas, for Ae. vigilax, tide height, mean air temperature and day length yielded a regression with an R(2) of 0.68. These models identify significant environmental drivers for both species and may be useful in the prediction of future outbreaks, particularly of Ae. vigilax.
Collapse
Affiliation(s)
- M J Kokkinn
- Sansom Institute, University of South Australia, Adelaide, Australia.
| | | | | |
Collapse
|
29
|
Liby K, Yore MM, Roebuck BD, Baumgartner KJ, Honda T, Sundararajan C, Yoshizawa H, Gribble GW, Williams CR, Risingsong R, Royce DB, Dinkova-Kostova AT, Stephenson KK, Egner PA, Yates MS, Groopman JD, Kensler TW, Sporn MB. A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. Cancer Res 2008; 68:6727-33. [PMID: 18701497 DOI: 10.1158/0008-5472.can-08-1123] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
A novel acetylenic tricyclic bis-(cyano enone), TBE-31, is a lead compound in a series of tricyclic compounds with enone functionalities in rings A and C. Nanomolar concentrations of this potent multifunctional molecule suppress the induction of the inflammatory protein, inducible nitric oxide synthase, activate phase 2 cytoprotective enzymes in vitro and in vivo, block cell proliferation, and induce differentiation and apoptosis of leukemia cells. Oral administration of TBE-31 also significantly reduces formation of aflatoxin-DNA adducts and decreases size and number of aflatoxin-induced preneoplastic hepatic lesions in rats by >90%. Because of the two cyano enones in rings A and C, TBE-31 may directly interact with DTT and protein targets such as Keap1 that contain reactive cysteine residues. The above findings suggest that TBE-31 should also be tested for chemoprevention and chemotherapy in relevant models of cancer and against other chronic, degenerative diseases in which inflammation and oxidative stress contribute to disease pathogenesis.
Collapse
Affiliation(s)
- Karen Liby
- Dartmouth Medical School, Hanover, NH 03755, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Liby K, Risingsong R, Royce DB, Williams CR, Yore MM, Honda T, Gribble GW, Lamph WW, Vannini N, Sogno I, Albini A, Sporn MB. Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268. Clin Cancer Res 2008; 14:4556-63. [PMID: 18628471 PMCID: PMC5048101 DOI: 10.1158/1078-0432.ccr-08-0040] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Purpose To test whether the triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid methyl ester (CDDO-Me) and the rexinoid LG100268 (268) prevent the formation of estrogen receptor (ER) – negative mammary tumors or either arrest the growth or cause regression of established tumors in MMTV-neu mice. Experimental Design For prevention, mice were fed control diet, CDDO-Me (60 mg/kg diet), 268 (20 mg/kg diet), or the combination for 45 weeks. For treatment, mice with established tumors at least 4 mm in diameter were fed control diet, CDDO-Me (100 mg/kg diet), 268 (60 mg/kg diet), or the combination for 4 weeks. Results CDDO-Me and 268 significantly delayed the development of ER-negative tumors, with a 14- and 24-week delay, respectively, compared with the control group for the time required to reach 50% tumor incidence. The combination of CDDO-Me and 268 was significantly more potent than the individual drugs, as only one tumor was found in the combination group, after 45 weeks on diet, at which time all control animals had tumors. Treating established tumors with CDDO-Me arrested the growth of 86% of the tumors, and 268 induced tumor regression in 85% of tumors. CDDO-Me and 268 target different signaling pathways and cell types. CDDO-Me inhibited constitutive STAT3 phosphorylation and the degradation of IKBα in ER-negative breast cancer cells, whereas 268 blocked IKBα degradation and the release of interleukin-6 in RAW264.7 macrophage-like cells, inhibited the ability of endothelial cells to organize into networks, and blocked angiogenesis in vivo. Conclusions CDDO-Me and 268 are useful as individual drugs to prevent ER-negative mammary tumorigenesis and to treat established tumors. They synergize when used in combination for prevention.
Collapse
Affiliation(s)
- Karen Liby
- Department of Pharmacology, Dartmouth Medical School, Hanover, NH 03755, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Liby K, Black CC, Royce DB, Williams CR, Risingsong R, Yore MM, Liu X, Honda T, Gribble GW, Lamph WW, Sporn TA, Dmitrovsky E, Sporn MB. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther 2008; 7:1251-7. [PMID: 18483313 DOI: 10.1158/1535-7163.mct-08-0023] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Female A/J mice injected with the carcinogen vinyl carbamate develop atypical adenomatous hyperplasias in lungs 4 weeks after injection with the carcinogen. The number and severity of tumors then increase over time, making these mice a useful model for evaluating potential chemopreventive agents. The rexinoid LG100268 (LG268), a selective ligand for the retinoid X receptor, and the methyl amide of the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) both significantly reduced the number, size, and severity of the histopathology of lung tumors in female A/J mice when fed in diet for 14 to 20 weeks. The total tumor burden was 85% to 87% lower in mice fed LG268 and CDDO-MA than in controls, and the percentage of high-grade tumors decreased from 59% in the controls to 25% or 30% with CDDO-MA and LG268. Erlotinib, which is used to treat lung cancer patients and is an inhibitor of the epidermal growth factor receptor, was less effective in this model. Immunohistochemical staining of geminin, a marker of cell cycle progression, was higher in lung sections from control mice than in mice treated with LG268. Because rexinoids and triterpenoids signal through different biological pathways, they should be tested in combination for the prevention of lung cancer.
Collapse
Affiliation(s)
- Karen Liby
- Department of Pharmacology, Dartmouth Medical School, Hanover, NH 03755, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Liby K, Royce DB, Risingsong R, Williams CR, Wood MD, Chandraratna RA, Sporn MB. A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland. Clin Cancer Res 2007; 13:6237-43. [PMID: 17947492 DOI: 10.1158/1078-0432.ccr-07-1342] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE We evaluated the anti-inflammatory and growth-inhibitory properties of the novel rexinoid NRX194204 (4204) in vitro and then tested its ability to prevent and/or treat experimental lung and estrogen receptor (ER)-negative breast cancer in vivo. EXPERIMENTAL DESIGN In cell culture studies, we measured the ability of 4204 to block the effects of lipopolysaccharide and induce apoptosis. For the lung cancer prevention studies, A/J mice were injected with the carcinogen vinyl carbamate and then fed 4204 (30-60 mg/kg diet) for 15 weeks, beginning 1 week after the administration of the carcinogen. For breast cancer prevention studies, mouse mammary tumor virus-neu mice were fed control diet or 4204 (20 mg/kg diet) for 50 weeks; for treatment, tumors at least 32 mm3 in size were allowed to form, and then mice were fed control diet or 4204 (60 mg/kg diet) for 4 weeks. RESULTS Low nanomolar concentrations of 4204 blocked the ability of lipopolysaccharide and tumor necrosis factor-alpha to induce the release of nitric oxide and interleukin 6 and the degradation of IKBalpha in RAW264.7 macrophage-like cells. In the A/J mouse model of lung cancer, 4204 significantly (P < 0.05) reduced the number and size of tumors on the surface of the lungs and reduced the total tumor volume per slide by 64% to 81% compared with the control group. In mouse mammary tumor virus-neu mice, 4204 not only delayed the development of ER-negative mammary tumors in the prevention studies but also caused marked tumor regression (92%) or growth arrest (8%) in all of the mammary tumors when used therapeutically. CONCLUSIONS The combined anti-inflammatory and anticarcinogenic actions of 4204 suggest that it is a promising new rexinoid that should be considered for future clinical trials.
Collapse
Affiliation(s)
- Karen Liby
- Department of Pharmacology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA
| | | | | | | | | | | | | |
Collapse
|
33
|
Liby K, Honda T, Williams CR, Risingsong R, Royce DB, Suh N, Dinkova-Kostova AT, Stephenson KK, Talalay P, Sundararajan C, Gribble GW, Sporn MB. Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities. Mol Cancer Ther 2007; 6:2113-9. [PMID: 17620440 DOI: 10.1158/1535-7163.mct-07-0180] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Betulinic acid (BA), a pentacyclic triterpene isolated from birch bark and other plants, selectively inhibits the growth of human cancer cell lines. However, the poor potency of BA hinders its clinical development, despite a lack of toxicity in animal studies even at high concentrations. Here, we describe six BA derivatives that are markedly more potent than BA for inhibiting inducible nitric oxide synthase, activating phase 2 cytoprotective enzymes, and inducing apoptosis in cancer cells and in Bax/Bak(-/-) fibroblasts, which lack two key proteins involved in the intrinsic, mitochondrial-dependent apoptotic pathway. Notably, adding a cyano-enone functionality in the A ring of BA enhanced its cytoprotective properties, but replacing the cyano group with a methoxycarbonyl strikingly increased potency in the apoptosis assays. Higher plasma and tissue levels were obtained with the new BA analogues, especially CBA-Im [1-(2-cyano-3-oxolupa-1,20(29)-dien-28-oyl)imidazole], compared with BA itself and at concentrations that were active in vitro. These results suggest that BA is a useful platform for drug development, and the enhanced potency and varied biological activities of CBA-Im make it a promising candidate for further chemoprevention or chemotherapeutic studies.
Collapse
Affiliation(s)
- Karen Liby
- Dartmouth Medical School, Hanover, NH 03755, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, Gribble GW, Dmitrovsky E, Sporn TA, Sporn MB. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res 2007; 67:2414-9. [PMID: 17363558 DOI: 10.1158/0008-5472.can-06-4534] [Citation(s) in RCA: 121] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We report the first use of new synthetic triterpenoids to prevent lung cancer in experimental animals. Female A/J mice were treated with the mutagenic carcinogen vinyl carbamate, which induces adenocarcinoma of the lung in all animals within 16 weeks. If mice were fed either the methyl ester or the ethyl amide derivative of the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO-ME and CDDO-EA, respectively), beginning 1 week after dosing with carcinogen, the number, size, and severity of lung carcinomas were markedly reduced. The mechanisms of action of CDDO-ME and CDDO-EA that are germane to these in vivo findings are the following results shown here in cell culture: (a) suppression of the ability of IFN-gamma to induce de novo formation of nitric oxide synthase in a macrophage-like cell line RAW264.7, (b) induction of heme oxygenase-1 in these RAW cells, and (c) suppression of phosphorylation of the transcription factor signal transducers and activators of transcription 3 as well as induction of apoptosis in human lung cancer cell lines.
Collapse
Affiliation(s)
- Karen Liby
- Department of Pharmacology, Dartmouth Medical School, Hanover, NH 03755, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Williams CR, Wallman JF, Tyler MJ. Toxicity of green tree frog (Litoria caerulea) skin secretion to the blowfliesCalliphora stygia(Fabricius) andLucilia cuprina(Wiedemann) (Diptera: Calliphoridae). ACTA ACUST UNITED AC 2007. [DOI: 10.1111/j.1440-6055.1998.tb01551.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- CR Williams
- Department of Zoology, The University of Adelaide, South Australia 5005, Australia
| | - JF Wallman
- Department of Zoology, The University of Adelaide, South Australia 5005, Australia
| | - MJ Tyler
- Department of Zoology, The University of Adelaide, South Australia 5005, Australia
| |
Collapse
|
36
|
Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T, Gribble GW, Sporn MB, Letterio JJ. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 2007; 12:4288-93. [PMID: 16857804 DOI: 10.1158/1078-0432.ccr-06-0215] [Citation(s) in RCA: 96] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Excessive activity of the transcription factors known as signal transducers and activators of transcription (STAT) contributes to the development and progression of malignancy in many organs. It is, therefore, important to develop new drugs to control the STATs, particularly their phosphorylation state, which is required for their transcriptional activity. EXPERIMENTAL DESIGN Myeloma and lung cancer cells were treated with the new synthetic triterpenoid CDDO-Imidazolide, and STAT phosphorylation and apoptosis were evaluated by immunoblotting and fluorescence-activated cell sorting analysis. RESULTS We now report that CDDO-Imidazolide, previously shown to be a potent agent for control of inflammation, cell proliferation, and apoptosis, rapidly (within 30-60 minutes) and potently (at nanomolar levels) suppresses either constitutive or interleukin-6-induced STAT3 and STAT5 phosphorylation in human myeloma and lung cancer cells. Furthermore, in these cells, CDDO-Imidazolide also up-regulates critical inhibitors of STATs, such as suppressor of cytokine signaling-1 and SH2-containing phosphatase-1 (a tyrosine phosphatase). Moreover, gene array studies reported here show that CDDO-Imidazolide potently regulates the transcription of important genes that are targets of the STATs. CONCLUSIONS Our new data thus show that CDDO-Imidazolide is a potent suppressor of STAT signaling and provide a further mechanistic basis for future clinical use of this agent to control inflammation or cell proliferation.
Collapse
Affiliation(s)
- Karen Liby
- Dartmouth Medical School and Dartmouth College, Hanover, New Hampshire, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
The search for novel insect repellents has been driven by health concerns over established synthetic compounds such as diethyl-m-toluamide (DEET). Given the diversity of compounds known from frog skin and records of mosquito bite and ectoparasite infestation, the presence of mosquito repellents in frogs seemed plausible. We investigated frog skin secretions to confirm the existence of mosquito repellent properties. Litoria caerulea secretions were assessed for mosquito repellency by topical application on mice. The secretions provided protection against host-seeking Culex annulirostris mosquitoes. Olfactometer tests using aqueous washes of skin secretions from L. caerulea and four other frog species were conducted to determine whether volatile components were responsible for repellency. Volatiles from Litoria rubella and Uperoleia mjobergi secretions were repellent to C. annulirostris, albeit not as repellent as a DEET control. The demonstration of endogenous insect repellents in amphibians is novel, and demonstrates that many aspects of frog chemical ecology remain unexplored.
Collapse
Affiliation(s)
- C R Williams
- The University of Adelaide, School of Earth and Environmental Sciences, Adelaide, South Australia 5005, Australia.
| | | | | | | |
Collapse
|
38
|
Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim H, Brown P, Sporn MB. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin Cancer Res 2006; 12:5902-9. [PMID: 17020999 DOI: 10.1158/1078-0432.ccr-06-1119] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE We tested whether a selective estrogen receptor modulator (SERM) and a rexinoid are active for prevention and treatment in the mouse mammary tumor virus-neu mouse model of estrogen receptor-negative breast cancer. EXPERIMENTAL DESIGN For prevention, mice were fed a powdered control diet, the SERM arzoxifene (Arz, 20 mg/kg diet), the rexinoid LG100268 (268, 30 mg/kg diet), or the combination for 60 weeks. In a second prevention study, mice were fed Arz (6 mg/kg diet), 268 (30 mg/kg diet), the combination of Arz and 268, the SERM acolbifene (Acol, 3 mg/kg diet), or the combination of Acol and 268 for 52 weeks. For the treatment studies, mice with tumors were fed combinations of a SERM and 268 for 4 weeks. RESULTS The rexinoid 268 and the SERMs Arz and Acol, as individual drugs, delayed the development of estrogen receptor-negative tumors. Moreover, the combination of a SERM and 268 was strikingly synergistic, as no tumors developed in any mouse fed the combination of 268 and a SERM. Moreover, this drug combination also induced significant tumor regression when used therapeutically. These drugs did not inhibit transgene expression in vitro or in vivo, and the combination of Arz and 268 inhibited proliferation and induced apoptosis in the tumors. CONCLUSION The combination of a rexinoid and SERM should be considered for future clinical trials.
Collapse
Affiliation(s)
- Karen Liby
- Dartmouth Medical School, Hanover, NH 03755, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Honda T, Liby KT, Su X, Sundararajan C, Honda Y, Suh N, Risingsong R, Williams CR, Royce DB, Sporn MB, Gribble GW. Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A. Bioorg Med Chem Lett 2006; 16:6306-9. [PMID: 16996735 PMCID: PMC1950140 DOI: 10.1016/j.bmcl.2006.09.012] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2006] [Revised: 08/31/2006] [Accepted: 09/06/2006] [Indexed: 11/29/2022]
Abstract
Fifteen new betulinic acid analogues were designed, synthesized, and tested for anti-inflammatory activity. Many of these analogues effectively suppress nitric oxide (NO) production in RAW cells stimulated with interferon-gamma. Analogue 10 is highly and orally active in vivo for induction of the anti-inflammatory and cytoprotective enzyme, heme oxygenase-1.
Collapse
Affiliation(s)
- Tadashi Honda
- Department of Chemistry, Dartmouth College, Hanover, NH 03755, U.S.A
- *Corresponding authors. Tel.: +1 603 646 1591; fax: +1 603 646 3946; e-mail: (for T. H.). Tel.: +1 603 646 3118; fax: +1 603 646 3946; e-mail: (for G. W. G.)
| | - Karen T. Liby
- Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH 03755, U.S.A
| | - Xiaobo Su
- Department of Chemistry, Dartmouth College, Hanover, NH 03755, U.S.A
| | | | - Yukiko Honda
- Department of Chemistry, Dartmouth College, Hanover, NH 03755, U.S.A
| | - Nanjoo Suh
- Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH 03755, U.S.A
| | - Renee Risingsong
- Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH 03755, U.S.A
| | - Charlotte R. Williams
- Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH 03755, U.S.A
| | - Darlene B. Royce
- Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH 03755, U.S.A
| | - Michael B. Sporn
- Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH 03755, U.S.A
| | - Gordon W. Gribble
- Department of Chemistry, Dartmouth College, Hanover, NH 03755, U.S.A
- *Corresponding authors. Tel.: +1 603 646 1591; fax: +1 603 646 3946; e-mail: (for T. H.). Tel.: +1 603 646 3118; fax: +1 603 646 3946; e-mail: (for G. W. G.)
| |
Collapse
|
40
|
Russell RC, Webb CE, Williams CR, Ritchie SA. Mark-release-recapture study to measure dispersal of the mosquito Aedes aegypti in Cairns, Queensland, Australia. Med Vet Entomol 2005; 19:451-7. [PMID: 16336310 DOI: 10.1111/j.1365-2915.2005.00589.x] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
In Queensland, Australia, in response to isolated cases of dengue infection, larval control of the vector Aedes aegypti (L.) (Diptera: Culicidae) is targeted at breeding sites within 200 m of a case and interior spraying with a pyrethroid adulticide is targeted at premises within 100 m. To ascertain whether these limits are appropriate, we conducted a mark-release-recapture study to measure the dispersal of female Ae. aegypti in the city of Cairns where transmission occurs. Female mosquitoes reared from wild collected eggs were differentially marked with fluorescent dust depending on whether they were to be released blood-fed or non-blood-fed, and a total of 1,948 females was released. A total of 132 sticky ovitraps was set at 64 premises within a 200 m radius and collections of trapped adults were made at 5-15 days post-release. Sixty-seven females (3.4%) were recaptured, with the furthest being caught 200 m from the release point, and the mean distance travelled was 78 m. Overall, 23.1% of the recaptures outside the release site were taken beyond 100 m by day 15. Dispersal was comparable for both blood-fed and non-blood-fed releases. There was a significant tendency for dispersal to be in a north-westerly direction, probably because of the presence of numerous containers and heavy shading by trees in this direction and a busy road to the south of the release point that appeared to inhibit dispersal. The results suggest that adulticiding may have to be extended beyond 100 m if more than 8 days have elapsed since female Ae. aegypti could have fed upon a viraemic dengue case. The study also shows that dispersal is not random, and that it may be possible to maximize vector control by taking into account environmental factors that affect the direction of female mosquito flight.
Collapse
Affiliation(s)
- R C Russell
- Department of Medical Entomology, University of Sydney and ICPMR, Westmead Hospital, New South Wales, Australia.
| | | | | | | |
Collapse
|
41
|
Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A, Sporn MB. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 2005; 65:4789-98. [PMID: 15930299 DOI: 10.1158/0008-5472.can-04-4539] [Citation(s) in RCA: 220] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) and its derivative 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im) are multifunctional molecules with potent antiproliferative, differentiating, and anti-inflammatory activities. At nanomolar concentrations, these agents rapidly increase the expression of the cytoprotective heme oxygenase-1 (HO-1) enzyme in vitro and in vivo. Transfection studies using a series of reporter constructs show that activation of the human HO-1 promoter by the triterpenoids requires an antioxidant response element (ARE), a cyclic AMP response element, and an E Box sequence. Inactivation of one of these response elements alone partially reduces HO-1 induction, but mutations in all three sequences entirely eliminate promoter activity in response to the triterpenoids. Treatment with CDDO-Im also elevates protein levels of Nrf2, a transcription factor previously shown to bind ARE sequences, and increases expression of a number of antioxidant and detoxification genes regulated by Nrf2. The triterpenoids also reduce the formation of reactive oxygen species in cells challenged with tert-butyl hydroperoxide, but this cytoprotective activity is absent in Nrf2 deficient cells. These studies are the first to investigate the induction of the HO-1 and Nrf2/ARE pathways by CDDO and CDDO-Im, and our results suggest that further in vivo studies are needed to explore the chemopreventive and chemotherapeutic potential of the triterpenoids.
Collapse
Affiliation(s)
- Karen Liby
- Dartmouth Medical School and Dartmouth College, Hanover, New Hampshire 03755, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Honda T, Janosik T, Honda Y, Han J, Liby KT, Williams CR, Couch RD, Anderson AC, Sporn MB, Gribble GW. Design, Synthesis, and Biological Evaluation of Biotin Conjugates of 2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic Acid for the Isolation of the Protein Targets. J Med Chem 2004; 47:4923-32. [PMID: 15369396 DOI: 10.1021/jm049727e] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO, 1) and related compounds [for example, CDDO-Me (2) and CDDO-Im (3)] are potential anti-inflammatory, cancer chemopreventive, and chemotherapeutic agents. However, the mechanisms responsible for the multiple effects of CDDO are still unclear. Clarification of these mechanisms and particularly isolation of the protein targets are essential for the development of CDDO and its analogues as clinically useful drugs. Such knowledge would provide superior opportunities for designing new compounds with improved potency and selectivity. Therefore, to isolate protein targets using affinity chromatography with immobilized streptavidin as a carrier, we have designed and synthesized C-17 and C-23 biotin conjugates of CDDO (4, 5, and 6) on the basis of our established structure-activity relationships. For the synthesis of 6, a new important precursor, 23-hydroxy-CDDO-Me (29) was synthesized from 20 by a C-23 oxidation protocol, which involves cyclopalladation of the C-4 methyl group from a 3-one oxime. The inhibitory activity of C-23 conjugate 6 is only about 3 times less potent than the mother compound, CDDO, against the proliferation of MCF-7 breast cancer cells. Consequently, 6 may be a very promising tool for the isolation of the protein targets of CDDO.
Collapse
Affiliation(s)
- Tadashi Honda
- Department of Chemistry, Dartmouth College, 6128 Burke Laboratory, Hanover, New Hampshire 03755, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Singh SK, Manjure S, Stott P, Shetty A, Iversen SA, Williams CR. Does routine blood bone biochemistry predict vitamin D insufficiency in elderly patients with low-velocity fractures? J Orthop Surg (Hong Kong) 2004; 12:31-4. [PMID: 15237119 DOI: 10.1177/230949900401200107] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
PURPOSE Vitamin D deficiency impairs bone mineralisation and can predispose individuals to fractures. This study aimed at testing whether measurement of plasma calcium, alkaline phosphatase, and phosphate levels could detect vitamin D insufficiency. METHODS During a 10-week winter period from December 2000 to February 2001, all elderly patients presenting to a general hospital in Brighton--British seaside town--with a fracture of the proximal femur and without known bone mineralisation problems were invited to participate in the study. RESULTS 23 (63.9%) of the 36 eligible patients had insufficient levels of vitamin D, with a plasma concentration of less than 30 nmol/L. The mean parathyroid hormone level was 56 pg/mL (range, 12-193 pg/mL). 11 of the 36 patients had an elevated level of parathyroid hormone were insufficient in vitamin D. The mean plasma concentration of calcium was 2.30 mmol/L (range, 2.05-2.98 mmol/L). The mean phosphate level was 0.98 mmol/L (range, 0.40-1.79 mmol/L), and the mean alkaline phosphatase level was 91 IU/L (range, 46-127 IU/L). There was poor correlation between vitamin D insufficiency and plasma calcium, alkaline phosphatase, or phosphate levels. CONCLUSION Plasma calcium, alkaline phosphatase, and phosphate testing cannot detect vitamin D insufficiency. We recommend that vitamin D and calcium supplementation be considered for patients with low-energy hip fractures.
Collapse
Affiliation(s)
- S K Singh
- Royal Sussex County Hospital, Brighton, UK.
| | | | | | | | | | | |
Collapse
|
44
|
Rendi MH, Suh N, Lamph WW, Krajewski S, Reed JC, Heyman RA, Berchuck A, Liby K, Risingsong R, Royce DB, Williams CR, Sporn MB. The Selective Estrogen Receptor Modulator Arzoxifene and the Rexinoid LG100268 Cooperate to Promote Transforming Growth Factor β-Dependent Apoptosis in Breast Cancer. Cancer Res 2004; 64:3566-71. [PMID: 15150113 DOI: 10.1158/0008-5472.can-04-0234] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We show that the selective estrogen receptor modulator arzoxifene (Arz) and the rexinoid LG100268 (268) synergize to promote apoptosis in a rat model of estrogen receptor-positive breast carcinoma and in estrogen receptor-positive human breast cancer cells in culture. We also show that it is not necessary to administer Arz and 268 continuously during tumor progression to prevent cancer in the rat model because dosing of these drugs in combination for relatively short periods, each followed by drug-free rests, is highly effective. This new approach to chemoprevention uses high doses of drugs that are too toxic for long-term administration. However, when given for short periods, the agents are nontoxic and still induce apoptosis in breast cancer cells. We also show that the ability of the two drugs to induce apoptosis is the combined result of induction of transforming growth factor beta by Arz, together with inhibition of the prosurvival nuclear factor kappaB and phosphatidylinositol 3' kinase signaling pathways by 268. The new protocol we have developed for chemoprevention allows the efficacious and safe administration of 268 and Arz, and these agents now should be considered for clinical use.
Collapse
Affiliation(s)
- Mara H Rendi
- Dartmouth Medical School, Hanover, New Hampshire 03755, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, Gribble GW, Leesnitzer LM, Stimmel JB, Willson TM, Rosen E, Sporn MB. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 2003; 9:2798-806. [PMID: 12855660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Abstract
1[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im) is a novel synthetic triterpenoid more potent than its parent compound, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO), both in vitro and in vivo. CDDO-Im is highly active in suppressing cellular proliferation of human leukemia and breast cancer cell lines (IC(50), approximately 10-30 nM). In U937 leukemia cells, CDDO-Im also induces monocytic differentiation as measured by increased cell surface expression of CD11b and CD36. In each of these assays, CDDO-Im is several-fold more active than CDDO. Although CDDO and CDDO-Im both bind and transactivate peroxisome proliferator-activated receptor (PPAR) gamma, the irreversible PPARgamma antagonist GW9662 does not block the ability of either CDDO or CDDO-Im to induce differentiation; moreover, PPARgamma-null fibroblasts are still sensitive to the growth-suppressive effects of CDDO. Thus, CDDO-Im has significant actions independent of PPARgamma transactivation. In addition, the rexinoid LG100268 and the deltanoid ILX23-7553 (ILX7553) synergize with CDDO and CDDO-Im to induce differentiation. In vivo, CDDO-Im is a potent inhibitor of de novo inducible nitric oxide synthase expression in primary mouse macrophages. Moreover, CDDO-Im inhibits growth of B16 murine melanoma and L1210 murine leukemia cells in vivo. The potent effects of CDDO-Im, both in vitro and in vivo, suggest it should be considered for clinical use.
Collapse
Affiliation(s)
- Andrew E Place
- Department of Pharmacology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Suh N, Roberts AB, Birkey Reffey S, Miyazono K, Itoh S, ten Dijke P, Heiss EH, Place AE, Risingsong R, Williams CR, Honda T, Gribble GW, Sporn MB. Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Res 2003; 63:1371-6. [PMID: 12649201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
We have studied the effects of two new synthetic triterpenoids, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) and its derivative, 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole (CDDO-Im), on transforming growth factor (TGF)-beta/Smad signaling. These agents, at nanomolar concentrations, increase the expression of TGF-beta-dependent genes, such as those for plasminogen activator inhibitor 1 and the type II TGF-beta receptor, and they synergize with TGF-beta in this regard. They prolong the activation of Smad2 induced by TGF-beta and markedly enhance the ability of Smad3 to activate a Smad binding element, CAGA-luciferase. In transfection assays, they reverse the inhibitory effects of Smad7. CDDO and CDDO-Im also enhance Smad signaling in the pathways of two other members of the TGF-beta superfamily, namely, activin and bone morphogenetic protein. Finally, these triterpenoids induce expression of the transcriptional coactivator p300-CBP-associated factor and synergize with TGF-beta in this regard. These are the first studies to report enhancement of Smad signaling by synthetic triterpenoids and should further their optimal use for applications in prevention or treatment of diseases in which there is aberrant function of TGF-beta.
Collapse
MESH Headings
- Acetyltransferases/biosynthesis
- Animals
- Cell Cycle Proteins/biosynthesis
- DNA-Binding Proteins/metabolism
- DNA-Binding Proteins/physiology
- Drug Synergism
- Histone Acetyltransferases
- Imidazoles/pharmacology
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/genetics
- Leukemia, Promyelocytic, Acute/metabolism
- Lung/cytology
- Lung/metabolism
- Macrophages/drug effects
- Macrophages/enzymology
- Mice
- Mink
- Nitric Oxide Synthase/antagonists & inhibitors
- Nitric Oxide Synthase/biosynthesis
- Nitric Oxide Synthase Type II
- Oleanolic Acid/analogs & derivatives
- Oleanolic Acid/pharmacology
- Plasminogen Activator Inhibitor 1/genetics
- Plasminogen Activator Inhibitor 1/metabolism
- Promoter Regions, Genetic/drug effects
- Protein Serine-Threonine Kinases
- RNA, Messenger/biosynthesis
- RNA, Messenger/genetics
- Receptor, Transforming Growth Factor-beta Type II
- Receptors, Transforming Growth Factor beta/biosynthesis
- Receptors, Transforming Growth Factor beta/genetics
- Signal Transduction/drug effects
- Smad2 Protein
- Smad7 Protein
- Terpenes/pharmacology
- Trans-Activators/metabolism
- Trans-Activators/physiology
- Transcription Factors
- Transforming Growth Factor beta/metabolism
- Transforming Growth Factor beta/pharmacology
- Transforming Growth Factor beta/physiology
- Transforming Growth Factor beta1
- Triterpenes/pharmacology
- p300-CBP Transcription Factors
Collapse
Affiliation(s)
- Nanjoo Suh
- Dartmouth Medical School and Dartmouth College, Hanover, New Hampshire 03755, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Suh N, Lamph WW, Glasebrook AL, Grese TA, Palkowitz AD, Williams CR, Risingsong R, Farris MR, Heyman RA, Sporn MB. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin Cancer Res 2002; 8:3270-5. [PMID: 12374698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Abstract
The selective estrogen receptor modulator arzoxifene and the rexinoid LG 100268 were active not only as single agents for prevention and treatment of breast cancer in the rat model that uses nitrosomethylurea as the carcinogen but also showed striking synergy, both preventively and therapeutically, in a series of six experiments with a total of 465 rats. Mechanistic studies in cell culture reported here suggest that enhancement of stromal-epithelial interactions may contribute to this synergy. The possible clinical use of the combination of arzoxifene and LG 100268 for prevention of breast cancer in women at high risk, for treatment of women in the adjuvant setting, or for treatment of end-stage disease should now be considered.
Collapse
Affiliation(s)
- Nanjoo Suh
- Department of Pharmacology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Beebe NW, van den Hurk AF, Chapman HF, Frances SP, Williams CR, Cooper RD. Development and evaluation of a species diagnostic polymerase chain reaction-restriction fragment-length polymorphism procedure for cryptic members of the Culex sitiens (Diptera: Culicidae) subgroup in Australia and the southwest Pacific. J Med Entomol 2002; 39:362-369. [PMID: 11931037 DOI: 10.1603/0022-2585-39.2.362] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Members of the Culex sitiens subgroup are important vectors of arboviruses, including Japanese encephalitis virus, Murray Valley encephalitis virus and Ross River virus. Of the eight described species, Cx. annulirostris Skuse, Cx. sitiens Wiedemann, and Cx. palpalis Taylor appear to be the most abundant and widespread throughout northern Australia and Papua New Guinea (PNG). Recent investigations using allozymes have shown this subgroup to contain cryptic species that possess overlapping adult morphology. We report the development of a polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) procedure that reliably separates these three species. This procedure utilizes the sequence variation in the ribosomal DNA ITS1 and demonstrates species-specific PCR-RFLP profiles from both colony and field collected material. Assessment of the consistency of this procedure was undertaken on mosquitoes sampled from a wide geographic area including Australia, PNG, and the Solomon Islands. Overlapping adult morphology was observed for Cx. annulirostris and Cx. palpalis in both northern Queensland and PNG and for all three species at one site in northwest Queensland.
Collapse
Affiliation(s)
- N W Beebe
- Molecular Parasitology Unit, University of Technology, Sydney, New South Wales, Australia.
| | | | | | | | | | | |
Collapse
|
49
|
Abstract
PURPOSE We determine the usefulness of ultrasonography as a screening modality to support the diagnosis of posterior urethral valves. MATERIALS AND METHODS A retrospective chart analysis was performed of 93 consecutive boys with newly diagnosed posterior urethral valves from August 1985 through February 1999. Of the 93 boys 65, including 62 who underwent renal and bladder ultrasonography, had preoperative renal sonography available and constitute our study population. Patient age range at presentation was newborn to 13 years, with 33 of the 65 boys presenting as infants (age 1 year or younger). Presentation included fetal hydronephrosis in 13 cases, urinary tract infection in 18, voiding dysfunction in 9, abdominal mass in 6, renal insufficiency in 5, failure to thrive in 4, hematuria in 1 and other in 9. RESULTS Preoperative sonography identified bilateral hydronephrosis in 48 boys (74%), unilateral hydronephrosis in 9 (14%) and no hydronephrosis in 8 (12%). Bladder sonography revealed an abnormal bladder (thickened, trabeculated and/or significantly distended) in 54 boys (87%). An abnormal bladder was seen in 43 of the 46 boys with bilateral hydronephrosis, 6 of 8 boys with unilateral hydronephrosis and 5 of 8 with normal upper tracts. Only 3 of the 62 boys (5%) had a normal upper tract and bladder. The sensitivity of renal ultrasonography in suspecting posterior urethral valves was 88%, while sensitivity of renal-bladder ultrasonography was 95%. When stratifying for age younger than 4 years and 4 or older, the sensitivity of predicting posterior urethral valves with renal-bladder ultrasonography was 87% and 98%, respectively. CONCLUSIONS While voiding cystourethrography remains the imaging gold standard for the diagnosis of posterior urethral valves, renal-bladder ultrasonography is an appropriate screening study for a boy suspected to have the condition. Renal-bladder ultrasonography may prove particularly useful in the evaluation of the boy with significant voiding dysfunction before deciding on a more invasive study, such as voiding cystourethrography.
Collapse
Affiliation(s)
- C R Williams
- Section of Pediatric Urology, and Division of Urology, Department of Surgery, University of Alabama at Birmingham, Children's Hospital, Birmingham, Alabama, USA
| | | | | |
Collapse
|
50
|
Abstract
PURPOSE We determine the usefulness of ultrasonography as a screening modality to support the diagnosis of posterior urethral valves. MATERIALS AND METHODS A retrospective chart analysis was performed of 93 consecutive boys with newly diagnosed posterior urethral valves from August 1985 through February 1999. Of the 93 boys 65, including 62 who underwent renal and bladder ultrasonography, had preoperative renal sonography available and constitute our study population. Patient age range at presentation was newborn to 13 years, with 33 of the 65 boys presenting as infants (age 1 year or younger). Presentation included fetal hydronephrosis in 13 cases, urinary tract infection in 18, voiding dysfunction in 9, abdominal mass in 6, renal insufficiency in 5, failure to thrive in 4, hematuria in 1 and other in 9. RESULTS Preoperative sonography identified bilateral hydronephrosis in 48 boys (74%), unilateral hydronephrosis in 9 (14%) and no hydronephrosis in 8 (12%). Bladder sonography revealed an abnormal bladder (thickened, trabeculated and/or significantly distended) in 54 boys (87%). An abnormal bladder was seen in 43 of the 46 boys with bilateral hydronephrosis, 6 of 8 boys with unilateral hydronephrosis and 5 of 8 with normal upper tracts. Only 3 of the 62 boys (5%) had a normal upper tract and bladder. The sensitivity of renal ultrasonography in suspecting posterior urethral valves was 88%, while sensitivity of renal-bladder ultrasonography was 95%. When stratifying for age younger than 4 years and 4 or older, the sensitivity of predicting posterior urethral valves with renal-bladder ultrasonography was 87% and 98%, respectively. CONCLUSIONS While voiding cystourethrography remains the imaging gold standard for the diagnosis of posterior urethral valves, renal-bladder ultrasonography is an appropriate screening study for a boy suspected to have the condition. Renal-bladder ultrasonography may prove particularly useful in the evaluation of the boy with significant voiding dysfunction before deciding on a more invasive study, such as voiding cystourethrography.
Collapse
Affiliation(s)
- C R Williams
- Section of Pediatric Urology, and Division of Urology, Department of Surgery, University of Alabama at Birmingham, Children's Hospital, Birmingham, Alabama, USA
| | | | | |
Collapse
|